Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Tirzepatide (Mounjaro and Zepbound) Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even greater weight loss in clinical trials compared to semaglutide
Last reviewed: June 11, 2026 Last updated: June 11, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
PubMed laboratory research record [PMID: 33835907] PubMed record related to this compound for laboratory literature review
Pak J Biochem Mol Biol
Furthermore, in July 2018, Sanofi invested about USD 74.1 million in China for establishing an R&D hub to enhance its global reach
US$ 26.69
US$ 20.43
US$ 21.77
US$ 23.54
